BioSpace News Archive

Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), a leading developer of spider silk based fibers, announces that it has submitted its formal application to list the Company’s common stock on the Nasdaq Capital Market. “After significantly strengthening our technology, business model, and corporate governance, to position Kraig Labs for future growth, an uplisting to the Nasdaq Capital Market is the natural evolution for the Comp

Additionally, Sutro’s partner Merck KGaA, Darmstadt, Germany, will be unveiling preclinical data from the collaboration’s pre-Development Candidate, a first-in-class bispecific antibody-drug conjugate targeting EGFR and MUC1 [09-June-2020] SOUTH SAN FRANCISCO, Calif. , June 9, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery,

RenovoRx , an innovator in targeted cancer therapy, today announced the United States Patent and Trademark Office issued U.S. Patent 15,807,011. This new patent broadly covers its unique therapeu

Today at Veeva Summit Online, Veeva Systems (NYSE: VEEV) announced Veeva Link for KAM, a new solution that gives commercial and medical teams accurate customer data and real-time insights for key account management.

CytoSorbents Corporation (NASDAQ:CTSO), a critical care immunotherapy leader specializing in blood purification, announced today that it was awarded a Defense Health Agency Small Business Technology Transfer (STTR) Phase III contract, valued at up to $2,897,172 over 2 years, to advance its HemoDefend-BGA plasma and whole b

BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain disorders, today announced that it will report its first quarter 2020 financial results and operational highlights on June 24, 2020.

New Telehealth Program Provides Emergency and Inpatient Care When It’s Needed Most

OPKO Health Inc. announced that the Japan Phase 3 clinical trial met its primary and secondary objectives, and demonstrated that the efficacy and safety of somatrogon administered weekly was comparable to GENOTROPIN® for injection administered once-daily as measured by annual height velocity after 12 months of treatment in treatment-naïve Japanese pre-pubertal children with GHD.

CureDuchenne Ventures, the venture funding arm of CureDuchenne, a leading global nonprofit dedicated to funding and finding a cure for Duchenne muscular dystrophy, announced the first ever CureDuchenne Ventures 2020 Pitch Contest.

VolparaEnterprise Data Analysis Shows Mammography Screening Volumes are Quickly Increasing